Suites 3808-3811, CITIC Square
Shanghai 200041

Arnold & Porter's Shanghai office provides both international and PRC clients with immediate and direct access to experienced lawyers based in Shanghai, China’s emerging business center. Our Asia Pacific group, based in the United States and Shanghai, is active in China and other parts of Asia, including Japan, Singapore, Korea, Indonesia, the Philippines and Australia.

In the corporate arena, our Shanghai office assists multinational corporations and private equity funds in their investments in the PRC. Lawyers in the office are experienced in corporate transactions involving cross-border investments, international joint ventures and wholly foreign-owned enterprises, and also advise PRC companies regarding international investments and other matters in the United States. They have worked with clients in the automotive, chemicals, consumer products, construction, financial services, hotel, natural resources, publishing, semiconductor, and telecommunications industries in China.

Our Asia Pacific practice advises Asia-based companies on corporate transactions (including mergers and acquisitions, private equity and direct investments, securities offerings, project finance and infrastructure development, and corporate restructuring), taxation, trademarks and patent licensing and protection, employment, dispute resolution, FCPA, CFIUS/Exon-Florio, antitrust and other United States and foreign government regulatory issues. We represented the largest Chinese appliance company as it first entered into the United States. market and assisted it to establish its business and legal infrastructure in the United States. We also represented one of the largest state-owned companies in China in a derivatives-related trial in federal court in New York. Arnold & Porter has a wealth of lawyers based in the United States and China with experience in advising Asian clients on Asia-related or Asia-based matters.


Chambers Asia-Pacific
Corporate Investigations/Anti-Corruption (China) (2019)
Life Sciences (China) (2019)

Email Disclaimer